Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Kintara Therapeutics stock
Learn how to easily invest in Kintara Therapeutics stock.
Kintara Therapeutics is a biotechnology business based in the US. Kintara Therapeutics shares (KTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Kintara Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Kintara Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – KTRA. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Kintara Therapeutics stock price (NASDAQ: KTRA)Use our graph to track the performance of KTRA stocks over time.
Kintara Therapeutics shares at a glance
|Latest market close||$6.56|
|52-week range||$3.50 - $24.90|
|50-day moving average||$7.25|
|200-day moving average||$8.87|
|Wall St. target price||$150.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.64|
Buy Kintara Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Kintara Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kintara Therapeutics price performance over time
|1 week (2023-01-23)||8.25%|
|1 month (2022-12-30)||-4.79%|
|3 months (2022-10-28)||5,809.91%|
|6 months (2022-07-29)||3,370.90%|
|1 year (2022-01-28)||1,654.01%|
|2 years (2021-01-29)||264.44%|
|3 years (2020-01-30)||1,057.78%|
|5 years (2018-01-30)||396.97%|
Kintara Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-75.09%|
|Return on equity TTM||-147.95%|
|Market capitalisation||$9.3 million|
TTM: trailing 12 months
Kintara Therapeutics share dividends
We're not expecting Kintara Therapeutics to pay a dividend over the next 12 months.
Have Kintara Therapeutics's shares ever split?
Kintara Therapeutics's shares were split on a 1:50 basis on 13 November 2022. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kintara Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Kintara Therapeutics shares which in turn could have impacted Kintara Therapeutics's share price.
Kintara Therapeutics share price volatility
Over the last 12 months, Kintara Therapeutics's shares have ranged in value from as little as $3.5022 up to $24.895. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kintara Therapeutics's is 1.0415. This would suggest that Kintara Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Kintara Therapeutics overview
Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China.
Frequently asked questionsWhat percentage of Kintara Therapeutics is owned by insiders or institutions?
Currently 6.298% of Kintara Therapeutics shares are held by insiders and 4.64% by institutions. How many people work for Kintara Therapeutics?
Latest data suggests 3 work at Kintara Therapeutics. When does the fiscal year end for Kintara Therapeutics?
Kintara Therapeutics's fiscal year ends in June. Where is Kintara Therapeutics based?
Kintara Therapeutics's address is: 9920 Pacific Heights Blvd, San Diego, CA, United States, 92121 What is Kintara Therapeutics's ISIN number?
Kintara Therapeutics's international securities identification number is: US49720K1016
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert